What question did this study set out to answer?

This research aims to evaluate the impact of matching therapies to genomic biomarkers on survival in patients with advanced solid tumors.

March 7, 2026

Genomic Therapy Matching in Rare and Refractory Cancers

Key Points

This research aims to evaluate the impact of matching therapies to genomic biomarkers on survival in patients with advanced solid tumors.
Cohort study design focusing on patients with advanced solid tumors
Assessment of genomic biomarkers for therapy matching
Evaluation of survival outcomes in correlation with clinical trial evidence
Improved survival was noted when genomic therapy was supported by prospective clinical trial evidence
Findings highlight the importance of an evidence-based framework for therapy prioritization

Abstract

In this cohort study of patients with advanced solid tumors, matching therapies to genomic biomarkers was associated with improved survival only when supported by prospective clinical trial evidence. These findings support using an evidence-based framework to prioritize genomically guided therapies.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Frank P. Lin

Subotheni Thavaneswaran

John P. Grady

Journals

JAMA Oncology

Actions

Institutions

The University of Sydney

UNSW Sydney

The University of Western Australia

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Genomic Therapy Matching in Rare and Refractory Cancers

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider